Besponsa a New Treatment Option for Patients with Relapsed/Refractory B-Cell ALL

JHOP Web Exclusives - FDA News & Updates, Online Only

On August 17, 2017, the FDA approved inotuzumab ozogamicin (Besponsa; Pfi­zer), a targeted therapy, for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The drug blocks cancer growth by binding to B-cell ALL cells that express CD22. The FDA designated inotuzumab ozogamicin as an orphan drug and applied its priority review for this approval.

“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low. These patients have few treatments available and today’s approval provides a new, targeted treatment option,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The FDA approval of inotuzumab ozogamicin was based on a randomized clinical trial of 326 patients with relapsed or refractory B-cell ALL who had received 1 or 2 previous treatments. Among the 218 evaluable patients, 35.8% of those receiving inotuzumab ozogamicin achieved complete remission that lasted a median of 8 months. Of the patients who received an alternative chemotherapy regimen, 17.4% achieved complete remission lasting a median of 4.9 months.

The common side effects reported with inotuzumab ozogamicin include thrombocytopenia, neutropenia, leukopenia, infection, anemia, fatigue, hemorrhage, pyrexia, nausea, headache, febrile neutropenia, liver damage, abdominal pain, and hyper­bilirubinemia. Serious side effects attributed to the use of inotuzumab ozogamicin include myelosuppression, infusion-related reactions, and QT interval prolongation.

Inotuzumab ozogamicin was approved with a boxed warning about the risk for hepatotoxicity, including veno-occlusive disease or sinusoidal obstruction syndrome, as well as the increased mortality risk in patients who use the drug after certain stem-cell transplants.

Related Items
Actemra First FDA-Approved Treatment for CAR T-Cell–Induced Severe Cytokine Release Syndrome
JHOP Web Exclusives published on October 30, 2017 in FDA News & Updates, Online Only
Mylotarg Now Approved for the Treatment of Patients with CD33-Positive AML
JHOP Web Exclusives published on October 30, 2017 in FDA News & Updates, Online Only
Nivolumab Receives New Indication for dMMR and MSI-H Metastatic Colorectal Cancer
JHOP Web Exclusives published on October 30, 2017 in FDA News & Updates, Online Only
Kymriah First Gene Therapy Approved by the FDA, Indicated for Young Patients with B-Cell ALL and CD19
JHOP Web Exclusives published on October 9, 2017 in FDA News & Updates, Online Only
Olaparib Tablet Receives New Indication in Ovarian Cancer
TON - September 2017, Vol 10, No 5 published on September 10, 2017 in FDA News & Updates
FDA News - September 2017
JHOP Web Exclusives published on September 8, 2017 in FDA News & Updates, Online Only
FDA News - August 2017
JHOP Web Exclusives published on August 1, 2017 in FDA News & Updates, Online Only
FDA News - June 2017
JHOP Web Exclusives published on June 1, 2017 in FDA News & Updates, Online Only
Cancer Drug Approvals: A Tale of 2 Views
Sharon Donovan
TON - May 2017, Vol 10, No 3 published on May 17, 2017 in FDA News & Updates
FDA News - April 2017: Additional Items
JHOP Web Exclusives published on April 14, 2017 in FDA News & Updates, Online Only
Last modified: October 9, 2017